Literature DB >> 30626218

Hormone replacement therapy and prevention of chronic conditions.

M Gambacciani1, A Cagnacci2, S Lello3.   

Abstract

Nowadays, postmenopausal women are largely undertreated. Analysis of conflicting results among different studies suggests that hormone replacement therapy (HRT) can prevent osteoporosis and cardiovascular disease in symptomatic, early postmenopausal women. In fact, climacteric symptoms are related to an increased risk of chronic conditions, including hypertension and cardiovascular disease. Different scientific societies have pointed out that patient selection, timing of initiation, and the choice of the type and dose of HRT used are the major determinants of the ultimate effect of HRT on women's health and quality of life in selected women. HRT may prevent chronic conditions when started in symptomatic women before the age of 60 years or within 10 years of the onset of the menopause, taking into consideration the characteristics and risk profiles of each given woman. The bulk of scientific evidence from preclinical, clinical, epidemiological, and also randomized studies indicates that wisely selected HRT is generally useful and rarely dangerous. Following simple and well-established rules, HRT benefits outweigh all of the possible risks. Progestogen choice can make the difference in terms of cardiovascular disease benefits.

Entities:  

Keywords:  Menopause; cardiovascular disease; hormone replacement therapy; hypertension; osteoporosis

Mesh:

Substances:

Year:  2019        PMID: 30626218     DOI: 10.1080/13697137.2018.1551347

Source DB:  PubMed          Journal:  Climacteric        ISSN: 1369-7137            Impact factor:   3.005


  7 in total

Review 1.  A Nutraceutical Approach to Menopausal Complaints.

Authors:  Pasquale De Franciscis; Nicola Colacurci; Gaetano Riemma; Anna Conte; Erika Pittana; Maurizio Guida; Antonio Schiattarella
Journal:  Medicina (Kaunas)       Date:  2019-08-28       Impact factor: 2.430

2.  Conjugated linoleic acid prompts bone formation in ovariectomized osteoporotic rats and weakens osteoclast formation after treatment with ultraviolet B.

Authors:  Zhongshu Shan; Yanyan Zhao; Zhixue Qiu; Suonan Angxiu; Yong Gu; Junming Luo; Hongtao Bi; Wei Luo; Rui Xiong; Siqing Ma; Zhao He; Liang Chen
Journal:  Ann Transl Med       Date:  2021-03

3.  Immunoglobulin G glycome composition in transition from premenopause to postmenopause.

Authors:  Helena Deriš; Domagoj Kifer; Ana Cindrić; Tea Petrović; Ana Cvetko; Irena Trbojević-Akmačić; Ivana Kolčić; Ozren Polašek; Louise Newson; Tim Spector; Cristina Menni; Gordan Lauc
Journal:  iScience       Date:  2022-02-10

4.  The effects of chronic estradiol treatment on opioid self-administration in intact female rats.

Authors:  Jessica L Sharp; Sarah B Ethridge; Shannon L Ballard; Kenzie M Potter; Karl T Schmidt; Mark A Smith
Journal:  Drug Alcohol Depend       Date:  2021-06-18       Impact factor: 4.852

5.  Hormone therapy for first-line management of menopausal symptoms: Practical recommendations.

Authors:  Santiago Palacios; John C Stevenson; Katrin Schaudig; Monika Lukasiewicz; Alessandra Graziottin
Journal:  Womens Health (Lond)       Date:  2019 Jan-Dec

Review 6.  "Bridging the Gap" Everything that Could Have Been Avoided If We Had Applied Gender Medicine, Pharmacogenetics and Personalized Medicine in the Gender-Omics and Sex-Omics Era.

Authors:  Donato Gemmati; Katia Varani; Barbara Bramanti; Roberta Piva; Gloria Bonaccorsi; Alessandro Trentini; Maria Cristina Manfrinato; Veronica Tisato; Alessandra Carè; Tiziana Bellini
Journal:  Int J Mol Sci       Date:  2019-12-31       Impact factor: 5.923

7.  The Interventional Effects of Tubson-2 Decoction on Ovariectomized Rats as Determined by a Combination of Network Pharmacology and Metabolomics.

Authors:  Fan Yang; Xin Dong; Feixiang Ma; Feng Xu; Jie Liu; Jingkun Lu; Chunyan Li; Ren Bu; Peifeng Xue
Journal:  Front Pharmacol       Date:  2020-10-14       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.